ClinicalTrials.govpublic full text
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
pulmonary disease, chronic obstructive, long-acting muscarinic antagonist, long-acting beta-agonist, chronic obstructive pulmonary disease, vilanterol, umeclidinium, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 993885
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.